title: [FDG-PET and endometrial cancer].
abstract: FDG-PET is widely used for the diagnosis, the staging and the search for recurrence of many tumors. However, there are currently no recommendations for its use in endometrial cancer. This article is an update of the literature data to enable everyone to form an opinion on the subject. Future prospects are considered.
authors.affiliation: Centre Oscar-Lambret, service de médecine nucléaire, Lille Cedex, France. h-gauthier@o-lambret.fr
authors.forename: Hélène
authors.initials: H
authors.lastname: Kolesnikov-Gauthier
authors.forename: Philippe
authors.initials: P
authors.lastname: Carpentier
mesh_terms: D016889:Endometrial Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D005189:False Positive Reactions; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D008207:Lymphatic Metastasis; D008279:Magnetic Resonance Imaging / Q000379:methods; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D011960:Receptors, Estrogen / Q000032:analysis; D012680:Sensitivity and Specificity
chemical_list: D019275:Radiopharmaceuticals; D011960:Receptors, Estrogen; D019788:Fluorodeoxyglucose F18